55 results about "Colony formation" patented technology

Aspects of the present disclosure relate to a method of colony enumeration. The method includes identifying colony forming units of microorganisms in a combined image using a pretrained deep learning model on a colony enumeration device. The method can include providing a plurality of identification characteristics of the colony forming units to an interaction component such that the interaction component can project at least some of the plurality of identification characteristics onto the combined image.

A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 1×1010 CFU / g, and a viability loss of less than 1 log unit / g after one month at a temperature of 40° C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.

The application relates to the field of biological medicine, and particularly relates to application of a TMEM119 gene or protein in development of an anti-gastric cancer drug, and particularly to application of a TMEM119 inhibitor in preparation of an anti-gastric cancer drug, wherein the inhibitor can be a small-molecule nucleotide for targeted knockdown of the TMEM119 gene or protein, the small-molecule nucleotide is shRNA or siRNA, the shRNA is a double-stranded oligonucleotide composed of complementary base sequences shown in SEQ ID NO. 1-2 or SEQ ID NO. 3-4; and the siRNA has a guide strand with a base sequence shown in SEQ ID NO. 7 or SEQ ID NO. 8. Experiments prove that when the expression of the TMEM119 gene of human gastric cancer cells is knocked down, the viability and the colony formation ability of the human gastric cancer cells are significantly reduced, thereby inhibiting the proliferation and survival of the gastric cancer cells, and further achieving the effect of restraining the occurrence, development, recurrence or metastasis of the gastric cancer.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The invention relates to application of an IP6 synthesis related kinase inhibitor in tumor radiotherapy sensitization. According to the application, CRISPR / Cas9 is used in vitro for screening important kinases in cells, it is found that the important kinases IPPK and ITPK1 participating in IP6 synthesis are related to radiotherapy sensitivity, and the research value of IPPK and ITPK1 serving as radiotherapy sensitization targets is further verified through cell colony formation experiments, mouse tumor-bearing induced radiotherapy tolerant cells and patient transcriptome data. In the aspect of mechanism and effect, it is found that targeted inhibition of IPPK and ITPK1 can promote lipid peroxidation induced by Fenton reaction by improving the level of free ferrous ions, so that ferroptosis is easier to occur, and sensitization can be achieved on radiotherapy which also causes lipid peroxidation. The invention provides a potential strategy for comprehensive treatment of malignant tumors, and has important practical significance for formulation of an accurate treatment scheme of malignant tumors clinically.

This useful solution, in the field of biotechnology and regenerative medicine, relates to a process for enhancing the efficiency of induced pluripotent stem cell (iPSC) colony formation from human peripheral blood mononuclear cells (PBMCs). The solution aims to overcome the low reprogramming efficiency, unstable colony formation, and limited iPSC cloning rates commonly encountered in PBMC iPSC generation processes. The technical essence of the solution lies in the synchronized optimization of the reprogramming process, including pre-activating PBMCs with an appropriate cytokine combination at predetermined times before reprogramming, using a non-integrated Sendai virus system under optimized transformation conditions, switching culture media at defined intervals to promote cell state transitions, and applying a selection, enrichment, and stabilization process for iPSC cloning in the initial passages after colony formation.The process also incorporates cell line quality control steps through assessment of residual Sendai virus RNA removal and mycoplasma contamination testing during line maintenance. Experimental results show that the proposed process increases the number of iPSC colonies formed, improves the rate of establishing stable iPSC lines, and enhances cell homogeneity and pluripotency maintenance. The solution can be applied in basic research, pathogenesis modeling, drug screening, regenerative medicine, and studies using induced pluripotent stem cells derived from human peripheral blood cells.

The application provides application of glutaroyl-CoA dehydrogenase in inducing ferroptosis of liver cancer cells, and belongs to the technical field of biotechnology.The application provides application of glutaroyl-CoA dehydrogenase (GCDH) in preparing products for evaluating risk of liver cancer and evaluating prognosis risk of liver cancer, and the tumor stage and T grade can be estimated by detecting the expression amount of GCDH, and the survival effect of liver cancer patients is evaluated.The application provides application of the overexpression reagent of GCDH in preparing products for inhibiting proliferation of liver cancer cells and inducing ferroptosis of liver cancer cells, and the ferroptosis of liver cancer cells is promoted by overexpressing GCDH in cells, and the colony formation ability of liver cancer cells is reduced.Further, the application provides application of the overexpression reagent of GCDH combined with a CA9 inhibitor in preparing products for inhibiting proliferation of liver cancer cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

This invention provides a human embryonic stem cell expansion culture medium, comprising DMEM / F12 medium, ITS-A, HEPES, magnesium ascorbate phosphate, non-essential amino acids, bFGF, FGF2-G3, GlutaMAX, LY-333531, gentamicin sulfate, Y27632, and CHIR99021. Y-27632 inhibits pluripotent stem cell apoptosis, improves adhesion efficiency, maintains pluripotency and colony formation ability; CHIR99021 enhances the self-renewal of pluripotent stem cells and inhibits their differentiation; LY-333531 inhibits spontaneous differentiation of pluripotent stem cells; and gentamicin sulfate reduces the risk of contamination during culture. The culture medium provided by this invention is serum-free, free of allogeneic substances, has a simple composition, and offers excellent expansion speed, effectively maintaining long-term stable passage of human embryonic stem cells, providing stable technical support for scientific research.

According to the isolated culture identification and key marker detection method for the down producing goat hair follicle stem cells, trypsin and EDTA are used for jointly digesting skin tissue, and high-activity cells are efficiently obtained; a culture medium containing various growth factors is adopted for culture, and cell proliferation and stemness maintenance are promoted. And identifying and integrating morphological observation, growth curve determination and clone formation experiment to accurately judge the characteristics of the cells. Immunofluorescent staining and real-time fluorescent quantitative PCR are applied to key marker detection, and expression of markers such as CK15, CD34 and beta1 integrin is detected with high sensitivity. The method is high in separation efficiency, accurate in identification and sensitive in marker detection, can provide sufficient high-quality cells for the research on the hair follicle stem cells of the cashmere goat, assists in deeply understanding the biological characteristics and the regulation mechanism of the cells, and is of great significance for improving the yield and quality of cashmere and promoting the development of related biotechnologies.

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.

This invention relates to the field of biomedical technology, and in particular to the application of hD1R protein in the preparation of drugs for the treatment of AML. Addressing the current lack of systematic and in-depth research on whether hD1R protein can directly act on AML cells and whether it has a synergistic effect with existing standard chemotherapy drugs (such as anthracyclines), this invention, through a series of in vivo and in vitro experiments and the construction of a NOD / SCID mouse transplantation model, confirms that hD1R protein alone can effectively inhibit AML cell proliferation, induce apoptosis, inhibit AML cell colony formation, and downregulate the expression of the key anti-apoptotic gene Bcl2 in AML cells. It also confirms that hD1R treatment can significantly prolong the survival of model mice. Furthermore, by setting up a Dox+hD1R group (combined experimental group), it is confirmed that when hD1R protein is used in combination with anthracycline chemotherapy drugs, it exhibits significant synergistic effects in inhibiting AML cell proliferation, promoting AML cell apoptosis, downregulating the expression of the anti-apoptotic gene Bcl2 in AML cells, and inhibiting AML cell colony formation.

The invention provides an application of FGF4 (fibroblast growth factor 4) as a drug target in treatment of enameloblastoma, relates to the technical field of biological medicines, finds a potential effect of the FGF4 in the enameloblastoma for the first time, proves an inhibition effect of the FGF4 on tumor growth, proves that the FGF4 can be used as a treatment target of the enameloblastoma, and proves that the FGF4 gene is knocked down in an enameloblastoma cell line, so that the treatment effect on the enameloblastoma is obviously improved. Cell proliferation, cell migration, cell invasion and cell colony formation can be inhibited; in an animal body, the FGF4 gene is knocked down to inhibit the growth of the enameloblastoma, which shows that the FGF4 has the effect of regulating and controlling the growth of the enameloblastoma, and the FGF4 inhibitor can inhibit the proliferation, migration, invasion and cell colony formation of an enameloblastoma cell line and inhibit the growth of the enameloblastoma. A new treatment target is provided for prevention and / or treatment of the glamoblastoma, and the application has a wide clinical application value.

This invention discloses the role of the small molecule compound RX4 in the preparation of anti-colon cancer drugs. The structure of RX4 is shown in Figure (1). Our experimental results show that RX4 can inhibit the proliferation and colony formation of colon cancer cell lines RKO, HCT-116, and SW620 in a concentration-dependent manner, inhibit cell migration, and induce apoptosis, thereby achieving anti-tumor biological activity.

The invention discloses application of 2-hydroxycinnamic acid in treatment of gastric cancer, according to the application, the influence of supernate of lactobacillus salivarius or lactobacillus crispatus on gastric cancer cell apoptosis is detected through a flow technology, and the 2-hydroxycinnamic acid is found to be capable of promoting the gastric cancer cell apoptosis and inhibiting the activity of gastric cancer organs. A metabolite in a supernatant of lactobacillus salivarius CICC23175 or lactobacillus crispatus CGMCC1.2743 screened by non-target metabolite omics contains 2-hydroxycinnamic acid, and the gastric cancer cytotoxic resistance of 2-hydroxycinnamic acid is deeply studied to find that the 2-hydroxycinnamic acid not only has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration, but also has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration. In addition, the 2-hydroxycinnamic acid can also increase the proportion of cells in a G1 / G0 period of a cell cycle, promote apoptosis of gastric cancer cells, and find that the inhibition effect of the 2-hydroxycinnamic acid on proliferation of gastric cancer organs is integrally higher than that of normal gastric epithelium organs.

The invention belongs to the technical field of biological cell visual detection, and particularly relates to a method for detecting the proliferation capacity of cells in a three-dimensional porous microcarrier material, which comprises the following steps: respectively preparing a cell suspension and a porous microcarrier material filled with a complete culture medium solution, uniformly mixing and culturing; digesting the microcarrier material; cleaning, filtering and collecting the microcarrier material gathered above the screen; preparing a low-melting-point agarose solution, uniformly mixing the low-melting-point agarose solution with the complete culture medium solution to serve as a bottom culture plate / observing and monitoring the cooling temperature of the solution; uniformly mixing a low-melting-point agarose solution with the cooling temperature of 38 + / -2 DEG C and a microcarrier material, and inversely placing above the bottom culture plate to form a middle layer; adding a complete culture medium solution to the upper surface of the middle layer to form a liquid nutrient moisturizing layer; placing the culture material in an incubator, and standing and culturing; and the proliferation activity of the cells in the microcarrier material is judged by calculating the formation rate of the microcarrier cell colonies.

The application provides a serum-free cell cryopreservation solution for epidermal stem cells and a preparation method and application thereof, and specifically belongs to the technical field of stem cell cryopreservation.The serum-free cell cryopreservation solution for epidermal stem cells comprises the following components in the following amounts: 0 g / L to 50 g / L raffinose, 3 g / L to 30 g / L dextran, 0% to 30% (volume percent) glycerol, 0% to 10% (volume percent) DMSO, 0% to 30% (volume percent) platelet lysate, and the balance of Ham's F-12; wherein the values of DMSO and glycerol are not both 0%. The serum-free cell cryopreservation solution can significantly improve the proliferation activity and colony formation ability of epidermal stem cells after resuscitation.

The present application relates to the field of biological medicine, and particularly relates to a drug composition for reversing lenvatinib drug resistance and application thereof. One object of the present application is to provide a drug composition containing cubenix and lenvatinib. Through the synergistic effect of cubenix and lenvatinib, the inhibitory effect on liver cancer lenvatinib drug-resistant cells is significantly improved, at the same time, the lenvatinib drug-resistant cell colony formation can be significantly inhibited, the lenvatinib drug-resistant cell apoptosis is promoted, and a better tumor inhibition effect is achieved in the liver cancer tumor-bearing mouse experiment.

This invention discloses an acetyltransferase ARD1 inhibitor, D753-0266, and its application in the treatment of colorectal cancer, belonging to the field of biomedical technology. Through molecular dynamics simulations and binding energy calculations, it was found that the binding energy of D753-0266 to NAA10 can reach -68.12 kcal / mol. In vitro experiments show that D753-0266 can directly bind to and stabilize the ARD1 protein, downregulate its expression level, and dose-dependently inhibit the proliferation of colorectal cancer cells, while significantly inhibiting cell migration and colony formation. In vivo experiments show that D753-0266 effectively inhibits tumor growth in a mouse xenograft model and is well-tolerated. This inhibitor fills a research gap in the field of ARD1 targeting and can be used to prepare colorectal cancer therapeutic drugs, possessing high specificity and clinical translational potential.

This invention discloses the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, belonging to the field of biotechnology. This invention provides the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, wherein the drugs are capable of promoting CYYR1 gene overexpression. Experiments have shown that overexpression of CYYR1 can significantly inhibit the proliferation, invasion, and colony formation of YAP-highly activated breast cancer cells MDA-MB-231, and inhibit tumorigenesis and lung metastasis in nude mice. Therefore, the CYYR1 gene can be used as a drug, drug target, or target gene in gene therapy for the treatment of YAP-highly activated tumors. This invention provides new diagnostic and therapeutic ideas and methods for the treatment of YAP-highly activated tumors.

The present invention relates to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases comprising the same, and more specifically, to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases, the present invention relates to a high-purity umbilical cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen characteristics, a method for obtaining an umbilical cord blood-derived vascular endothelial progenitor cell by pre-treating umbilical cord blood, and a composition for preventing and treating ischemic diseases comprising the umbilical cord blood-derived vascular endothelial progenitor cell. The high-purity umbilical cord blood-derived vascular endothelial progenitor cell of the present invention exhibits colony formation, high proliferation ability, and high potential for angiogenesis in vivo, and thus can exhibit an excellent effect on the prevention or treatment of various ischemic diseases induced by blood vessel contraction or occlusion.

This invention discloses the application of UFSP2 in the auxiliary diagnosis or treatment of prostate cancer, belonging to the field of biomedical technology. Experimental verification revealed that UFSP2 can serve as a diagnostic biomarker for prostate cancer and also possesses the potential to predict biochemical recurrence. Furthermore, this invention found that inhibiting UFSP2 expression significantly enhances the proliferation, migration, and colony formation capabilities of cells; upregulating UFSP2 expression significantly inhibits these capabilities, indicating that UFSP2 can serve as a therapeutic target for prostate cancer. Further, upregulating UFSP2 expression can also enhance the sensitivity of cancer cells to the chemotherapy drug docetaxel, suggesting that enhancing UFSP2 helps improve the therapeutic effect of chemotherapy drugs on prostate cancer. In summary, this invention provides a new biomarker for the diagnosis of prostate cancer and offers new targets and approaches for its treatment.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for or comprising administering to an individual in need thereof an inhibitor of an inhibitory immune checkpoint molecule and / or a stimulatory immune checkpoint molecule and a formulation, wherein the formulation comprises at least two different species or genera of non-pathogenic, live bacteria, and each of the non-pathogenic, live bacteria comprise non-pathogenic colony forming live bacteria, a plurality of non-pathogenic germinable bacterial spores, or a combination thereof, and optionally the non-pathogenic bacteria or non-pathogenic bacteria arising from germination of the germinable spores can individually or together metabolize urolithin A from ellagic acid, or can individually or together synthesize urolithin A.

The present invention relates to an anticancer composition comprising *Jeonho* as an active ingredient. When using the composition, an anticancer composition capable of exhibiting an anticancer effect by inducing apoptosis of cancer cells and inhibiting cell proliferation or colony formation of cancer cells can be provided. By including the composition, an anticancer pharmaceutical composition and an anticancer functional food composition without the problem of side effects can be provided.

The present disclosure relates to a cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases containing the same, and more specifically, to a highly pure cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen properties, a method for obtaining a cord blood-derived vascular endothelial progenitor cell through preprocessing of cord blood, and a composition for preventing or treating ischemic disease containing the cord blood-derived vascular endothelial progenitor cell. The high-purity cord blood-derived vascular endothelial progenitor cell of the present disclosure exhibits colony formation and high proliferation ability and angiogenic potential in the body, and thus can exhibit excellent effects in the prevention or treatment of various ischemic diseases caused by vascular contraction or occlusion.

Six kinds of mixed microorganisms consisting of Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Burkholderia cepacian, and Enterobacter cloacae, and Candida albicans yeast are inoculated into the cosmetic to be tested for storage, and a sample collected from the cosmetic to be tested during the storage is inoculated into an agar medium to which tetrazolium blue is added and cultured, and the number of viable bacteria corresponding to the total number of colony forming units determined in a short time is reduced by a predetermined amount or more from the theoretical number of bacteria inoculated into the agar medium, and this is used as an evaluation criterion for preservation efficacy.

The present disclosure provides a fertilizer particle comprising a solid core and a continuous coating wherein the continuous coating is at least partially covering the solid core, and the continuous coating comprises from 20 to 90 weight% of a carrier selected from the group consisting of polyhydric alcohols and derivatives thereof, based on the total weight of the continuous coating, and from 102 to 1015 colony-forming units (CFU) / g of at least one bacteria, based on the total weight of the continuous coating. The present disclosure also provides a method for producing a fertilizer particle and the use of a fertilizer particle.

This invention belongs to the field of pluripotent stem cell culture, and relates to a culture medium additive, culture method, and culture medium for improving the proliferation rate of pluripotent stem cells. The additive is SUN11602; the additive is added to a basal culture medium with well-defined components. The technical solution of this application, while fully retaining and being compatible with existing culture medium formulations, significantly and safely improves the in vitro proliferation rate, colony formation rate, and population expansion efficiency of hPSCs by adding exogenous compounds without compromising hPSC pluripotency and genomic integrity.

The invention relates to the technical field of genetic engineering, and provides an application of histone H1.2 in preparation of drugs for inhibiting proliferation and growth of non-small cell lung cancer cells, and inhibition of proliferation and growth of the non-small cell lung cancer cells comprises inhibition of proliferation, non-anchoring dependent growth, movement and migration capabilities of the non-small cell lung cancer cells. By constructing an HA-H1.2-FLAG-pCDH overexpression vector, establishing a histone H1.2 overexpressed lung cancer cell line, and combining a series of functional verifications such as a clone formation experiment, an MTT experiment, a scratch experiment, a Transwell experiment and a Western blot experiment, it is proved that the histone H1.2 overexpression can significantly inhibit proliferation, non-anchoring dependent growth, movement and migration of non-small cell lung cancer cells and regulate and control the EMT process, and the histone H1.2 overexpression can significantly inhibit non-small cell lung cancer cell proliferation, non-anchoring dependent growth, movement and migration of non-small cell lung cancer cells. A new target spot is provided for treating the non-small cell lung cancer.